BusinessRich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's LymphomaBy Nasdaq OMXMar 14, 2018, 1:45 PM UTC
BusinessUPDATE: Rich Pharmaceuticals Retains Experienced Contract Research Organization to Assist with Clinical TrialsBy Nasdaq OMXDec 5, 2017, 5:35 PM UTC
BusinessRich Pharmaceuticals Retains Experienced Contact Research Organization to Assist with Clinical TrialsBy Nasdaq OMXDec 5, 2017, 3:35 PM UTC
